SB1461 amends Virginia’s Medicaid state plan statute, § 32.1-325, to add rapid whole genome sequencing for certain young children as a covered medical assistance service. Specifically, the bill requires Medicaid coverage for rapid whole genome sequencing for children age three or younger who are receiving inpatient hospital services in an intensive care unit. The bill defines the test as whole-genome analysis intended to identify disease-causing genetic changes, with preliminary results due within seven days and final results within 15 days of sample receipt, and it includes patient-only, duo, and trio sequencing.
The measure is framed as an emergency act and takes effect upon passage. In addition to the new sequencing coverage, the bill reenacts the broader Medicaid state plan provision in which Virginia lists required and authorized categories of covered services and administrative rules, including telemedicine, remote monitoring, durable medical equipment, cancer screenings, maternity care, transplant services, and other benefits. The practical legal effect is to direct the Department of Medical Assistance Services to include rapid whole genome sequencing in the state plan when federal approval and reimbursement conditions are met, thereby making the service reimbursable under Medicaid for the specified population.
The overall sentiment around the bill appears strongly favorable and noncontroversial. It passed the Senate 40-0 and the House 97-0, and it was reported unanimously from both the Senate Education and Health Committee and the House Health and Human Services Committee. The absence of recorded opposition suggests broad bipartisan support for expanding access to a high-acuity diagnostic tool for critically ill young children.
There is little evidence of substantive contention in the available record. Because no committee transcripts were provided, no specific objections, amendments, or debated policy tradeoffs are documented. The bill’s main policy question is the scope and cost of Medicaid coverage for an advanced genetic test, but the unanimous votes indicate that any concerns about fiscal impact, utilization, or federal approval were not enough to generate recorded opposition.
Overall, SB1461 is a targeted Medicaid coverage expansion aimed at improving diagnosis and treatment decisions for critically ill infants and toddlers. Its impact is limited to the state plan for medical assistance services, but it may affect hospitals, pediatric intensive care units, laboratories, Medicaid providers, and families of eligible children by creating a reimbursement pathway for rapid genomic testing.
The bill amends Virginia Code § 32.1-325, the statute governing the Medicaid state plan, by adding rapid whole genome sequencing for children age three and under in intensive care as a covered medical assistance service. It requires the Department of Medical Assistance Services to incorporate this benefit into the state plan, subject to federal law and CMS approval, and makes the act effective immediately as an emergency measure. The change primarily affects Medicaid administration, pediatric hospitals, genetic testing providers, and eligible families by creating a new reimbursable diagnostic service under the state plan.
The bill received unanimous support throughout the legislative process, with no recorded votes in opposition in committee or on the floor in either chamber. That voting pattern suggests broad agreement that the coverage expansion is medically beneficial and appropriate for critically ill young children. No committee discussion transcripts were provided, so the record does not show any organized public or legislative resistance.
No notable contention is documented in the available materials. The only likely policy issues are the cost of adding a high-tech genetic test to Medicaid and the need for federal approval and reimbursement compliance, but those concerns did not surface as recorded opposition. Because the bill passed unanimously, any disagreement appears to have been minimal or resolved before final votes.